Skip to main content
Premium Trial:

Request an Annual Quote

GC Genome/Celemics: SARS-CoV-2 BTSeq Sequencing Service

Korean firms GC Genome and Celemics have launched a SARS-CoV-2 sequencing service. As part of the service, GC Genome will use Celemics' Barcode-Tagged Sequencing (BTSeq) technology, which can analyze sequence sizes of less than 1 kb to a maximum of 30 kb with an error rate of less than .001 percent per base pair, the companies said. This enables analysis of both PCR products and full SARS-CoV-2 genomes. Turnaround time is usually less than 10 days but can be minimized to one day, the companies said. The partners said that the service can reveal information on the epidemiology and pathogenesis of the virus and enable mutant surveillance.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.